Healthequity (HQY) Research & Development (2013 - 2026)

Healthequity has reported Research & Development for 14 years, with the latest figure at $73.9 million in Q3 2026.

• On a quarterly basis, Research & Development rose 14.07% year-over-year to $73.9 million in Q3 2026; TTM through Jul 2026 was $278.0 million, a 10.7% increase from a year earlier, with the FY2026 full-year figure at $262.5 million, up 9.6% from the prior year.
• Research & Development was $73.9 million for Q3 2026 at Healthequity, up from $67.8 million in the prior quarter.
• The five-year high for Research & Development was $73.9 million in Q3 2026, with the low at $45.2 million in Q2 2022.
• Average Research & Development over 5 years is $58.0 million, with a median of $56.1 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Research & Development surged 42.11% in 2022, then grew 4.77% in 2024.
• Over 5 years, Research & Development stood at $48.9 million in 2022, then climbed by 13.75% to $55.6 million in 2023, then increased by 8.23% to $60.2 million in 2024, then climbed by 9.52% to $65.9 million in 2025, then grew by 12.15% to $73.9 million in 2026.
• The last three Research & Development figures came in at $73.9 million (Q3 2026), $67.8 million (Q2 2026), and $70.4 million (Q1 2026), per Business Quant data.